524636 OXYGENTAPH

Oxygenta Pharmaceutical Share Price

 

 

Start SIP in OXYGENTAPH

Start SIP

Performance

  • Low
  • ₹53
  • High
  • ₹56
  • 52 Week Low
  • ₹52
  • 52 Week High
  • ₹134
  • Open Price₹53
  • Previous Close₹54
  • Volume1,816

Investment Returns

  • Over 1 Month -9.13%
  • Over 3 Month -21.41%
  • Over 6 Month -54.26%
  • Over 1 Year -37.68%

Smart Investing Starts Here Start SIP with Oxygenta Pharmaceutical for Steady Growth!

Invest Now

Oxygenta Pharmaceutical Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -11.5
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 198
  • P/B Ratio
  • -5.4
  • Average True Range
  • 2.91
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -1.81
  • RSI
  • 37.29
  • MFI
  • 10.36

Oxygenta Pharmaceutical Financials

Oxygenta Pharmaceutical Technicals

EMA & SMA

Current Price
₹53.43
-0.2 (-0.37%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹55.98
  • 50 Day
  • ₹59.93
  • 100 Day
  • ₹67.01
  • 200 Day
  • ₹73.07

Resistance and Support

54.02 Pivot Speed
  • R3 57.53
  • R2 56.52
  • R1 55.03
  • S1 52.53
  • S2 51.52
  • S3 50.03

Oxygenta Pharmaceutical Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-07 Quarterly Results
2025-08-14 Quarterly Results
2025-05-30 Audited Results
2025-02-14 Quarterly Results
2024-11-14 Quarterly Results

Oxygenta Pharmaceutical F&O

Oxygenta Pharmaceutical Shareholding Pattern

57.95%
0.03%
36.55%
5.47%

Oxygenta Pharmaceutical FAQs

Oxygenta Pharmaceutical share price is ₹53 As on 03 January, 2026 | 00:15

The Market Cap of Oxygenta Pharmaceutical is ₹197.6 Cr As on 03 January, 2026 | 00:15

The P/E ratio of Oxygenta Pharmaceutical is -11.5 As on 03 January, 2026 | 00:15

The PB ratio of Oxygenta Pharmaceutical is -5.4 As on 03 January, 2026 | 00:15

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23